Заключение

Литература

Кодина Г.Е., Красикова Р.Н. Методы получения радиофармацевтических препаратов и радионуклидных генераторов для ядерной медицины.

КорсаковМ.В. Основы ПЭТ радиохимии. СПб., 2002. 180 с.

Красикова Р.Н., Кузнецова О.Ф., Федорова О.С., Мосевич И.К., Малеев В.И., Белоконь Ю.Н., Савельева Т.Ф., Сагиян А.С., Дадаян С.А., Петросян А.А. Асимметрический синтез 6-¹⁸F-L-FDOPA с использованием хиральных комплексов никеля (II) // Радиохимия. 2007. № 49. С. 449-454.

Adam M.J., Ruth T.J., Grierson J.R., Abeysekera B., Pate B.D. Routine synthesis of L-[¹⁸F]6-fluorodopa with fluorine-18 acetylhypofluorite // J. Nucl. Med. 1986. Vol. 7. P. 1462-1468.

Barrio J.R., Huang S-C., Phelps M.E. Biological imaging and the molecular basis of dopaminergic diseases. Biochem Pharmacol. 1997. Vol. 54. P 341-348.

Blessing G., Coenen H.H., Franken K., Qaim S.M. Production of [¹⁸F]F₂, H¹⁸F and ¹⁸Faq - using the ²⁰Ne(d, a)¹⁸F process // Appl. Radia. Isot. 1986. Vol. 37. P 1135-1139.

Cai L., Lu S., Pike VW. Chemistry with [¹⁸F]fluoride ion // Eur. J. Org. Chem. 2008. P 2853-73.

Coenen H.H., Elsinga P.H., Iwata R., Kilbourn M.R., Pillai M.R.A., Rajan M.G.R., Wagner H.N., Zaknun J.J. Fluorine-18 radiopharmaceuticals beyond [¹⁸F]FDG for use in oncology and neurosciences // Nucl. Med. Biol. 2010. Vol. 37. P 727-740.

CummingP., Gjedde A. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms // Synapse. 1998. Vol. 29. P 37-61.

DagherA., Owen A.M., BoeckerH., Brooks D.J. The role of the striatum andhippocampus in planning: a PET activation study in Parkinson’s disease // Brain.

De Vries E.F.J., Luurstema G., Brussermann M., Elsinga P.H., Vaalburg W. Fully automated synthesis module for the high yield one-pot preparation of 6-[¹⁸F]fluoro-L-DOPA // Appl. Radiat. Isot. 1999. Vol. 51. P. 389-394.

Elsinga P.H., Hatano K., Ishiwata K. PET tracers for imaging of the dopaminergic system // Curr. Med. Chem. 2006. Vol. 13. P 2139-2153.

Ermert J., Coenen H.H. Methods for ¹¹C- and ¹⁸F-labelling of amino acids and derivatives for positron emission tomography imaging // J. Label. Comp. Radiopharm. 2013. Vol. 56. P 225-236.

Farde L. Quantitative analysis of D2 dopamine receptor binding in the living human brain with PET // Science. 1986. Vol. 231. P 258-261.

Farde L., Halldin C., Stone-Elander S., Sedvall G. PET analysis of human dopamine receptor subtypes using ¹¹C-SCH 23390 and ¹¹C-raclopride // Psychopharmacology. 1987. Vol. 92. P. 278-284.

Forsback S., Eskola O., Haaparanta M., Bergman J., Solin O. Electrophilic synthesis of 6-[¹⁸F]fluoro-L- DOPA using post-target produced [¹⁸F]F₂ // Radiochim. Acta. 2008. Vol. 96. P. 845-848.

Fuchtner F., Angelberger P., KvaternikH., Hammerschmidt F., Simovc B.P., Steinbach J. Aspects of 6-[¹⁸F] fluoro-L-DOPA preparation: precursor synthesis, preparative HPLC purification and determination of radiochemical purity // Nucl. Med. Biol. 2002. Vol. 29. P. 477-481.

GarnettE.S., Firnau G., Nahmias C. Dopamine visualized in the basal ganglia of living man // Nature. 1983. Vol. 305. P. 137-138.

Halldin C., Farde L., Hogberg T., MohellN., HallH., Suhara T. et al. Carbon-11-FLB 457: a radioligand for extrastriatal D₂ dopamine receptors // J. Nucl. Med. 1995. Vol. 36. P. 1275-1281.

Halldin C., Gulyas B., Langer O., Farde L. Brain radioligands-state of the art and new trends // Q. J. Nucl. Med. 2001. Vol. 45. P. 139-152.

Halldin C., Erixon-Lindroth N., Pauli S., Chou Y.H., Okubo Y., Karlsson P.

Huang W.S., Chiang Y.H., Lin J.C. et al. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson’s disease patients // J. Nucl. Med. 2003. Vol. 44. P. 999-1005.

Koopmans K.P., Brouwers A.H., De Hooge M.N., Van der Horst-Schrivers A.N., Kema I.P., Wolffenbut- telB.H., De VriesE.G., JagerP.L. Carcinoid crisis after injection of 6-¹⁸F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid // J. Nucl. Med. 2005. Vol. 46. P. 1240-1243.

Krasikova R.N., Zaitsev V.V., Ametamey S.M., Kuznetsova O.F., Fedorova O.S., Mosevich I.K., Belokon Y.N., Vyskocild S., Shatik S.V, Nader M., Schubiger P.A. Catalytic enantioselective synthesis of ¹⁸F-Auorinat- ed a-amino acids under phase transfer conditions using (S)-NOBIN // Nucl. Med. Biol. 2004. Vol. 31. P. 597-603.

Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies // Neuroimage. 1996. Vol. 4. P. 153-158.

Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review // J. Cereb. Blood. Flow. Metab. 2000. Vol. 20. P. 423-429.

Lee C.M., Farde L. Using positron emission tomography to facilitate CNS drug development // Trends Pharmacol. Sci. 2006. Vol. 27. № 6. P. 310-316.

Lemaire C., Damhaut P., Plenevaux A., Comar D. Enantioselective synthesis of 6-[fluorine-18]-fluoro-L- dopa from no-carrier-added fluorine-18-fluoride // J. Nucl. Med. 1994. Vol. 35. P. 1996-2002.

Lemaire C., Gillet S., Guillouet S., Plenevaux A., Aerts J., Luxen. Highly enantioselective synthesis of nocarrier-added 6-[¹⁸F]Fluoro-L-dopa by chiral phase-transfer alkylation // Eur. J. Org. Chem. 2004. Vol. 13. P. 2899-2904.

LibertL.C., FranciX., PlenevauxA.R., Ooi T., Maruoka K., LuxenA.J., Lemaire C.F.

Mason N.S., Mathis C.A., Klunk W.E. Positron emission tomography radioligands for in vivo imaging of A_p plaques // J. Label. Compds. Radiopharm. 2013. Vol. 56. P. 89-95.

McCarthy T.J. Positron emission tomography imaging as a key enabling technology in drug development // Ernst. Schering. Res. Found Workshop. 2007. Vol. 62. P. 329-39.

Minn H., Kauhanen S., Seppanen M., Nuutila P. ¹⁸F-FDOPA: A multiple-target molecule // J. Nucl. Med. 2009. Vol. 50. P. 1915-1918.

Nagren K., Halldin C., Rinne J.O. Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease // Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37. P. 1575-1593.

Phelps M.E., Maziotta J.C., Schelbert H.R. - eds. Positron emission tomography and autoradiography. Principles and application for the brain and heart. NY, 1986.

Rowe C.C., Villemagne V.L. Brain amyloid imaging // J. Nucl. Med. 2011. Vol. 52. P. 1-8.

Schou M., Steiger C., Varrone A., Guilloteau D., Halldin C. Synthesis, radiolabeling and preliminary in vivo evaluation of [¹⁸F]FE-PE2I, a new probe for the dopamine transporter // Bioorg. Med. Chem. Lett. 2009. Vol. 19. P. 4843-4845.

Seibyl J.P., Chen W., Silverman D. H.S. 3,4-Dihydroxy-6-[¹⁸F]-Fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors // Sem. Nucl. Med. 2007. Vol. 37. P. 440-450.

Vandenberghe K., Van Laere, A. Ivanoiu A. et al. ¹⁸F-Autemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial // Ann. Neurol. 2010. Vol. 68. P. 319-329.

Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M., Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications // Arch. Neurol. 2007. Vol. 64. P. 1575-1579.

Wagner FM., Ermert J., Coenen H.H. Three-Step, «One-Pot» radiosynthesis of 6-fluoro-3,4-dihydroxy-L- phenylalanine by isotopic exchange. // J. Nucl. Med. 2009. Vol. 50. P. 1724-1729.

WahlR.L., Buchanan J.W. Principles and practice of positron emission tomography. Philadelphia, Lippincott: Williams & Wilkins, 2002. 462 p.